drugset / Trial / NCT05142865
Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label，single-arm, phase II exploratory study that evaluates the efficacy and safety of Camrelizumab combined with Chemotherapy （carboplatin or cisplatin + etoposide）and Apatinib as First Line treatment in Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas（EP-NEC）
Timeline
- Start
- 2022-01-14
- Primary completion
- 2024-01-14
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |